Potential effective treatment of shortening continuous erythropoietin receptor activator treatment interval combined with iron supplementation in hemodialysis patients

Our previous randomized controlled trial comparing the total dose of weekly versus biweekly continuous erythropoietin receptor activator (CERA) therapy to maintain optimal hemoglobin (Hb) levels showed no significant differences between the two therapies. This post-hoc analysis assessed whether the...

Full description

Bibliographic Details

Published in:	Journal of Pharmacological Sciences
Main Authors:	Yuki Kawai, Yoshiyuki Toya, Hiromichi Wakui, Tetsuya Fujikawa, Eiko Ueda, Kengo Azushima, Sho Kinguchi, Hiroshi Mitsuhashi, Tomoyuki Kawano, Tadashi Kuji, Satoshi Yamaguchi, Toshimasa Ohnishi, Kouichi Tamura
Format:	Article
Language:	English
Published:	Elsevier 2021-09-01
Subjects:	Erythropoietin-stimulating agent Iron deficiency Renal anemia Continuous erythropoietin receptor activator Iron metabolism
Online Access:	http://www.sciencedirect.com/science/article/pii/S1347861321000529